# Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

> **NCT04811040** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 32 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Oral Lenacapavir
- **DRUG:** Subcutaneous Lenacapavir
- **DRUG:** Teropavimab
- **DRUG:** Zinlirvimab

## Key facts

- **NCT ID:** NCT04811040
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-08
- **Primary completion:** 2022-06-09
- **Final completion:** 2023-10-26
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04811040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04811040, "Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04811040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*